Back to Search
Start Over
Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity
- Source :
- Curr Opin Infect Dis
- Publication Year :
- 2020
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2020.
-
Abstract
- PURPOSE OF THE REVIEW: The purpose of this review is to update information on treatment of T. vaginalis. Trichomonas vaginalis is estimated to be the most common treatable sexually transmitted infection (STI) In the world and is associated with poor birth outcomes, cervical cancer, sperm motility and morphology issues, and HIV acquisition and transmission. RECENT FINDINGS: The efficacy of the recommended 2 gram oral single-dose metronidazole (MTZ) for the treatment of T. vaginalis in women has recently been challenged. Two recent multi-centered randomized trials and a meta-analysis have demonstrated that the 7-day dose of MTZ 500 mg twice daily was nearly two times more efficacious at clearing infection compared to the 2 gram dose. Partner treatment is also essential, since up to 70% of male sexual partners can be infected and rescreening of treated women at 3-months is also recommended given the high repeat infection rates. Future studies should examine the importance of treating asymptomatic T. vaginalis, best treatment for men, the influence of the microbiome on treatment efficacy, and different formulations of intra-vaginal treatments for hypersensitivity. SUMMARY: 7 day 500 mg twice daily MTZ should be used as the first line treatment for T. vaginalis infected women.
- Subjects :
- Male
0301 basic medicine
Microbiology (medical)
Drug
medicine.medical_specialty
media_common.quotation_subject
030106 microbiology
Trichomonas
Antiprotozoal Agents
Sexually Transmitted Diseases
Trichomonas Infections
medicine.disease_cause
Article
Drug Hypersensitivity
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Recurrence
Metronidazole
Internal medicine
Trichomonas vaginalis
Humans
Medicine
030212 general & internal medicine
Sperm motility
media_common
Cervical cancer
Nitroimidazole
Dose-Response Relationship, Drug
biology
business.industry
Extramural
biology.organism_classification
medicine.disease
Infectious Diseases
chemistry
Nitroimidazoles
Female
business
Subjects
Details
- ISSN :
- 09517375
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Current Opinion in Infectious Diseases
- Accession number :
- edsair.doi.dedup.....6e107958423e78f6d526fcf50cf1b46e